Novartis AG (NOVN) - Medical Equipment - Deals and Alliances Profile

Novartis AG (NOVN) - Medical Equipment - Deals and Alliances Profile


  • Products Id :- GDME24864D
  • |
  • Pages: 225
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers eye care products through its subsidiary, Alcon; and generic medicines and biosimilars through Sandoz. Novartis carries out research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices in the Americas, Europe, the Middle East, Africa and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

Novartis AG (NOVN)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 7

List of Figures 9

Novartis AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 10

Novartis AG, Medical Equipment Deals By Type, 2012 to YTD 2018 11

Novartis AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 12

Novartis AG, Medical Equipment, Deals By Market, 2012 to YTD 2018 13

Novartis AG, Medical Equipment, Deals Summary, 2012 to YTD 2018 14

Novartis AG, Medical Equipment, Deal Details 23

Asset Purchase 23

GSK Consumer Healthcare to Acquire Quell technology from NeuroMetrix 23

Advanced Accelerator Applications to Acquire Two Production Sites in Germany 24

Advanced Accelerator Applications Acquires Positron Emission Tomography from GE Healthcare 25

SensoMotoric Sells Ophthalmic Division To Alcon Labs 26

Venture Financing 27

Pear Therapeutics Raises USD50 Million in Series B Financing 27

ImaginAb Raises USD7.7 Million in Venture Financing 29

Rani Therapeutics Raises USD39 Million in Series D Financing 30

Lemonaid Health Raises USD11 Million in Series A Financing 32

Atlas Genetics Raises USD35 Million in Series D Financing 33

Seventh Sense Biosystems Raises USD10 Million in Series C Financing 35

Rox Medical Raises USD40 Million in Series E Financing 37

Cota Raises Funds through Venture Financing 38

Rani Therapeutics Raises Funds in Financing 39

Ra Pharma Raises USD58.5 Million in Series B Financing 41

Autonomic Technologies Raises Additional USD5.5 Million in Series D Financing 43

MyoPowers Medical Raises USD5 Million in Venture Financing 45

Rani Therapeutics Raises USD25 Million in Series C Venture Financing 46

Autonomic Technologies Raises USD38 Million in Series D Financing 47

Merganser Biotech Raises USD28 Million in Series A Financing 49

Encore Vision Raises USD1 Million in Venture Financing 50

Atlas Genetics Raises USD20 Million in Series C Financing 51

Transcend Medical Raises USD7.2 Million in Venture Financing 53

BioNano Genomics Raises USD53 Million in Series C Venture Financing 54

Encore Vision Raises USD1.7 Million in Venture Financing 56

Seventh Sense Biosystems Raises USD16 Million in Series B Financing 57

ImaginAb Raises USD21 Million in Series B Venture Financing 59

Transcend Medical Raises USD 22 Million In Series C Venture Financing 60

Advanced Accelerator Applications Raises USD 56 Million In Venture Financing 61

Wavetec Vision Systems Raises USD 0.8 Million In Venture Financing 62

Encore Vision Secures USD5 Million in Venture Funding 63

Wavetec Vision Raises USD 11 Million In Series D-2 Financing 64

Advanced Accelerator Raises USD 6 Million In First Tranche Of Venture Financing 65

Proteus Digital Health Raises USD 63 Million In Series F Financing Round 66

Health XL Raises Funds Through Venture Financing 67

Wavetec Vision Raises USD 16.5 Million In Venture Financing 68

Advanced Animal Diagnostics Secures USD4 Million in Second Tranche of Series B Funding 69

ImaginAb Raises USD 12.5 Million In Series A Financing 70

WaveTec Vision Raises USD 1.5 Million In Venture Financing 71

Transcend Medical Secures USD16 Million in Series B Venture Funding 72

Private Equity 73

dievini Hopp BioTech Acquires Remaining Stake in LTS Lohmann Therapie-Systeme from Novartis and BWK 73

Partnerships 74

Novartis Enters into Collaboration and Licensing Agreement with Harvard University and Dana-Farber Cancer Institute 74

Alcon Enters into Licensing Agreement with Google for Smart Lens Technology 75

Klox Technologies Enters Into Licensing Agreement With Sandoz Canada 76

Adamis Pharma Enters into Distribution Agreement with Sandoz 77

Pear Therapeutics Enters into Agreement with Sandoz 78

Pear Therapeutics Enters into Agreement with Novartis 79

NuvoAir Enters into Agreement with Novartis 80

Advanced Accelerator Applications Enters into Distribution Agreement with Blue Earth Diagnostics 81

Propeller Health Enters into Agreement with Novartis Pharma 82

Itel Telecomunicazioni Enters into Agreement with Advanced Accelerator Applications 83

Alcon Laboratories Enters Into Partnership Agreement with PowerVision 84

Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 85

Alcon Laboratories Enters Into Partnership Agreement with TrueVision Systems 86

Novartis Enters into Agreement with Microsoft 87

MedinCell Enters into Agreement with Sandoz International 88

Thermo Fisher Scientific Enters into Agreement with Novartis and Pfizer 89

CorTechs Labs Enters into Agreement with Novartis Pharma 90

Eveon Enters into Agreement with Advanced Accelerator Applications 91

Qiagen Enters into Co-Development Agreement with Novartis 92

SomaLogic Extends Co-Development Agreement with Novartis 93

MolecularMD Enters Into Agreement With Novartis To Develop Companion Diagnostic Test For Chronic Myelogenous Leukemia 94

Advanced Accelerator Applications Enters Into Co-Development Agreement With University of Warsaw 95

Foundation Medicine Extends Co-Development Agreement With Novartis 96

Advanced Accelerator Enters into Licensing Agreement with Cancer Targeted Technology 97

Sunovion Pharma Enters into Licensing Agreement with Novartis 98

BioQuiddity Expands Licensing Agreement with Sandoz 99

Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 100

Novartis Enters into Licensing Agreement with Boston Scientific for Everolimus 101

Life Technologies Enters Into Licensing Agreement With Novartis 102

Themis Medicare Enters Into Licensing Agreement With Novartis India For Diclofenac Topical Gel 103

Equity Offering 104

Advanced Accelerator Applications Prices Public Offering of American Depositary Shares for USD172.5 Million 104

Advanced Accelerator Applications to Raise up to USD80 Million in IPO 106

Debt Offering 108

Novartis Raises USD925 Million in Public Offering of 0.5% Bonds Due 2023 108

Novartis Raises USD925 Million in Public Offering of 1.375% Notes Due 2030 109

Novartis Raises USD925 Million in Public Offering of 1.7% Notes Due 2038 110

Novartis Raises USD647.19 Million in Public Offering of International Bonds Due 2027 111

Novartis Raises USD1.3 Billion in Public Offering of International Bonds Due 2021 112

Novartis Raises USD561.78 Million in Public Offering of International Bonds Due 2028 113

Novartis Raises USD1.40 Billion in Public Offering of International Bonds Due 2023 114

Novartis Raises USD1.75 Billion in Public Offering of 3% Bonds Due 2025 115

Novartis Raises USD1.25 Billion in Public Offering of 4% Bonds Due 2045 116

Novartis Raises USD2.15 Billion in Public Offering of 3.4% Bonds Due 2024 117

Novartis Raises USD1.85 Billion in Public Offering of 4.4% Bonds Due 2044 118

Novartis Completes Public Offering Of 2.4% Senior Notes Due 2022 For USD 1.5 Billion 119

Novartis Completes Public Offering Of 3.7% Senior Notes Due 2042 For USD 500 Million 120

Asset Transactions 121

China NT Pharma to Acquire Miacalcic Injectable and Miacalcic Spray from Novartis for USD145 Million 121

Novartis Plans to Divest Assets of Alcon 122

Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 123

Acquisition 125

GlaxoSmithKline Acquires Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD13 Billion 125

Novartis Acquires Advanced Accelerator Applications for USD3.9 Billion 127

Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 129

Alcon Acquires Transcend Medical 131

Novartis May Acquire Genfit 132

Novartis Acquires Encore Vision 133

Novartis Acquires Ziarco Group 134

Advanced Accelerator Applications Acquires Remaining 49.9% Stake in Umbra Medical 135

Alcon Acquires WaveTec Vision Systems 136

Advanced Accelerator Applications Acquires Imaging Equipment 138

Advanced Accelerator Applications Acquires Barnatron 139

Advanced Accelerator Applications Acquires Catalana De Dispensacion 140

Novartis Acquires Vivacta For USD 90 Million 141

Alcon Acquires Endure Medical Systems, Technology Surgical Microscopes Provider 142

Novartis AG - Key Competitors 143

Novartis AG - Key Employees 144

Novartis AG - Locations And Subsidiaries 146

Head Office 146

Other Locations & Subsidiaries 146

Recent Developments 164

Strategy And Business Planning 164

Sep 25, 2018: Novartis to cut more than 2000 jobs in Switzerland and UK 164

Sep 25, 2018: Novartis proposes to exit Grimsby UK site by end of 2020 as part of global manufacturing network transformation 165

Sep 11, 2018: Nova Medical Centers opens occupational medicine clinic in El Paso, Texas 166

Jul 02, 2018: Novartis plans to spin-off eye care unit into standalone entity 167

Financial Announcements 168

Jul 18, 2018: Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company 168

Apr 19, 2018: Novartis delivered a strong first quarter and acted to become a more focused medicines company 173

Oct 24, 2017: Novartis delivered growth on top and bottom line in all divisions in Q3 177

Jul 18, 2017: Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products 182

Apr 25, 2017: Novartis delivered sales growth across all divisions as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued 187

Jan 25, 2017: Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback 191

Corporate Communications 197

Aug 14, 2018: Novartis names Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance Officer 197

May 16, 2018: Novartis announces changes to the Executive Committee 198

May 10, 2018: Novartis India reconstitutes Board appoints Milan Paleja as Vice Chairman Managing Director 199

Apr 19, 2018: Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer 200

Mar 12, 2018: Novartis announces changes to the Executive Committee to support strategic priorities 201

Dec 15, 2017: Novartis announces Oncology head to retire 202

Sep 04, 2017: Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018. 203

Aug 24, 2017: Novartis appoints Bertrand Bodson as Chief Digital Officer 204

May 08, 2017: Dr. Stephen S. Lane joins Alcon as Chief Medical Officer and Global Head Franchise Clinical Strategy 205

Feb 28, 2017: Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting 206

Government and Public Interest 207

Nov 28, 2017: Biosimilar drugs have the potential to save more than USD 54 billion 207

Product News 208

Jul 12, 2018: Novartis launches the Galaxies of Hope app, a digital experience for the Neuroendocrine Tumor (NET) cancer community 208

Jul 09, 2018: Microsoft and Partners Showcase a New 'Molecule' for Better Health Outcomes 209

Jul 06, 2018: Sandoz and its affiliate, Novartis Pharmaceuticals voluntarily recall select blister packages of products in the U.S. due to packaging requirements for child resistance 210

Apr 25, 2018: Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home 212

Jun 06, 2017: Alcon highlights product and service innovations at 40th BCLA, one of the largest international meetings dedicated to contact lenses 213

Other Significant Developments 215

Sep 11, 2018: Alcon confirms commitment to Switzerland ahead of proposed spinoff from Novartis 215

May 16, 2018: At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth 216

Sep 29, 2017: Alcon flagship AcrySof intraocular lens reaches 100 million implants and counting 217

Jun 05, 2017: Novartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancer 218

Mar 16, 2017: Alcon and Orbis celebrate new Flying Eye Hospitals visit to the UK 219

Mar 03, 2017: Alcon Launches New Digital Vision Care Marketing Portal for Eye Care Professionals 220

Mar 02, 2017: Alcon Supports Eye Health with Charitable Giving of Nearly $73 Million in 2016 and Renews Commitment to Think About Your Eyes 221

Jan 26, 2017: Novartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report 222

Jan 26, 2017: Achievement of sales milestone for COPD products 223

Jan 25, 2017: Seebri / Ultibro Breezhaler 2016 sales reach $512 million triggering $5 million milestone receipt 224

Appendix 225

Methodology 225

About GlobalData 225

Contact Us 225

Disclaimer 225

List of Figures

Novartis AG, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Novartis AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Novartis AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Novartis AG, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Novartis AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 10

Novartis AG, Medical Equipment, Deals by Type, 2012 to YTD 2018 11

Novartis AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 12

Novartis AG, Medical Equipment, Deals by Market, 2012 to YTD 2018 13

List of Tables

Novartis AG, Medical Equipment, Key Facts, 2017 2

Novartis AG, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Novartis AG, Medical Equipment, Deals By Year, 2012 to YTD 2018 10

Novartis AG, Medical Equipment Deals By Type, 2012 to YTD 2018 11

Novartis AG, Medical Equipment, Deals By Region, 2012 to YTD 2018 12

Novartis AG, Deals By Market, 2012 to YTD 2018 13

Novartis AG, Medical Equipment, Deals Summary, 2012 to YTD 2018 14

GSK Consumer Healthcare to Acquire Quell technology from NeuroMetrix 23

Advanced Accelerator Applications to Acquire Two Production Sites in Germany 24

Advanced Accelerator Applications Acquires Positron Emission Tomography from GE Healthcare 25

SensoMotoric Sells Ophthalmic Division To Alcon Labs 26

Pear Therapeutics Raises USD50 Million in Series B Financing 27

ImaginAb Raises USD7.7 Million in Venture Financing 29

Rani Therapeutics Raises USD39 Million in Series D Financing 30

Lemonaid Health Raises USD11 Million in Series A Financing 32

Atlas Genetics Raises USD35 Million in Series D Financing 33

Seventh Sense Biosystems Raises USD10 Million in Series C Financing 35

Rox Medical Raises USD40 Million in Series E Financing 37

Cota Raises Funds through Venture Financing 38

Rani Therapeutics Raises Funds in Financing 39

Ra Pharma Raises USD58.5 Million in Series B Financing 41

Autonomic Technologies Raises Additional USD5.5 Million in Series D Financing 43

MyoPowers Medical Raises USD5 Million in Venture Financing 45

Rani Therapeutics Raises USD25 Million in Series C Venture Financing 46

Autonomic Technologies Raises USD38 Million in Series D Financing 47

Merganser Biotech Raises USD28 Million in Series A Financing 49

Encore Vision Raises USD1 Million in Venture Financing 50

Atlas Genetics Raises USD20 Million in Series C Financing 51

Transcend Medical Raises USD7.2 Million in Venture Financing 53

BioNano Genomics Raises USD53 Million in Series C Venture Financing 54

Encore Vision Raises USD1.7 Million in Venture Financing 56

Seventh Sense Biosystems Raises USD16 Million in Series B Financing 57

ImaginAb Raises USD21 Million in Series B Venture Financing 59

Transcend Medical Raises USD 22 Million In Series C Venture Financing 60

Advanced Accelerator Applications Raises USD 56 Million In Venture Financing 61

Wavetec Vision Systems Raises USD 0.8 Million In Venture Financing 62

Encore Vision Secures USD5 Million in Venture Funding 63

Wavetec Vision Raises USD 11 Million In Series D-2 Financing 64

Advanced Accelerator Raises USD 6 Million In First Tranche Of Venture Financing 65

Proteus Digital Health Raises USD 63 Million In Series F Financing Round 66

Health XL Raises Funds Through Venture Financing 67

Wavetec Vision Raises USD 16.5 Million In Venture Financing 68

Advanced Animal Diagnostics Secures USD4 Million in Second Tranche of Series B Funding 69

ImaginAb Raises USD 12.5 Million In Series A Financing 70

WaveTec Vision Raises USD 1.5 Million In Venture Financing 71

Transcend Medical Secures USD16 Million in Series B Venture Funding 72

dievini Hopp BioTech Acquires Remaining Stake in LTS Lohmann Therapie-Systeme from Novartis and BWK 73

Novartis Enters into Collaboration and Licensing Agreement with Harvard University and Dana-Farber Cancer Institute 74

Alcon Enters into Licensing Agreement with Google for Smart Lens Technology 75

Klox Technologies Enters Into Licensing Agreement With Sandoz Canada 76

Adamis Pharma Enters into Distribution Agreement with Sandoz 77

Pear Therapeutics Enters into Agreement with Sandoz 78

Pear Therapeutics Enters into Agreement with Novartis 79

NuvoAir Enters into Agreement with Novartis 80

Advanced Accelerator Applications Enters into Distribution Agreement with Blue Earth Diagnostics 81

Propeller Health Enters into Agreement with Novartis Pharma 82

Itel Telecomunicazioni Enters into Agreement with Advanced Accelerator Applications 83

Alcon Laboratories Enters Into Partnership Agreement with PowerVision 84

Lupin Enters into Co-Marketing Agreement with Novartis Healthcare 85

Alcon Laboratories Enters Into Partnership Agreement with TrueVision Systems 86

Novartis Enters into Agreement with Microsoft 87

MedinCell Enters into Agreement with Sandoz International 88

Thermo Fisher Scientific Enters into Agreement with Novartis and Pfizer 89

CorTechs Labs Enters into Agreement with Novartis Pharma 90

Eveon Enters into Agreement with Advanced Accelerator Applications 91

Qiagen Enters into Co-Development Agreement with Novartis 92

SomaLogic Extends Co-Development Agreement with Novartis 93

MolecularMD Enters Into Agreement With Novartis To Develop Companion Diagnostic Test For Chronic Myelogenous Leukemia 94

Advanced Accelerator Applications Enters Into Co-Development Agreement With University of Warsaw 95

Foundation Medicine Extends Co-Development Agreement With Novartis 96

Advanced Accelerator Enters into Licensing Agreement with Cancer Targeted Technology 97

Sunovion Pharma Enters into Licensing Agreement with Novartis 98

BioQuiddity Expands Licensing Agreement with Sandoz 99

Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 100

Novartis Enters into Licensing Agreement with Boston Scientific for Everolimus 101

Life Technologies Enters Into Licensing Agreement With Novartis 102

Themis Medicare Enters Into Licensing Agreement With Novartis India For Diclofenac Topical Gel 103

Advanced Accelerator Applications Prices Public Offering of American Depositary Shares for USD172.5 Million 104

Advanced Accelerator Applications to Raise up to USD80 Million in IPO 106

Novartis Raises USD925 Million in Public Offering of 0.5% Bonds Due 2023 108

Novartis Raises USD925 Million in Public Offering of 1.375% Notes Due 2030 109

Novartis Raises USD925 Million in Public Offering of 1.7% Notes Due 2038 110

Novartis Raises USD647.19 Million in Public Offering of International Bonds Due 2027 111

Novartis Raises USD1.3 Billion in Public Offering of International Bonds Due 2021 112

Novartis Raises USD561.78 Million in Public Offering of International Bonds Due 2028 113

Novartis Raises USD1.40 Billion in Public Offering of International Bonds Due 2023 114

Novartis Raises USD1.75 Billion in Public Offering of 3% Bonds Due 2025 115

Novartis Raises USD1.25 Billion in Public Offering of 4% Bonds Due 2045 116

Novartis Raises USD2.15 Billion in Public Offering of 3.4% Bonds Due 2024 117

Novartis Raises USD1.85 Billion in Public Offering of 4.4% Bonds Due 2044 118

Novartis Completes Public Offering Of 2.4% Senior Notes Due 2022 For USD 1.5 Billion 119

Novartis Completes Public Offering Of 3.7% Senior Notes Due 2042 For USD 500 Million 120

China NT Pharma to Acquire Miacalcic Injectable and Miacalcic Spray from Novartis for USD145 Million 121

Novartis Plans to Divest Assets of Alcon 122

Grifols Acquires Blood Transfusion Diagnostics Business from Novartis for USD1.66 Billion 123

GlaxoSmithKline Acquires Remaining 36.5% Stake in GlaxoSmithKline Consumer Healthcare from Novartis for USD13 Billion 125

Novartis Acquires Advanced Accelerator Applications for USD3.9 Billion 127

Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 129

Alcon Acquires Transcend Medical 131

Novartis May Acquire Genfit 132

Novartis Acquires Encore Vision 133

Novartis Acquires Ziarco Group 134

Advanced Accelerator Applications Acquires Remaining 49.9% Stake in Umbra Medical 135

Alcon Acquires WaveTec Vision Systems 136

Advanced Accelerator Applications Acquires Imaging Equipment 138

Advanced Accelerator Applications Acquires Barnatron 139

Advanced Accelerator Applications Acquires Catalana De Dispensacion 140

Novartis Acquires Vivacta For USD 90 Million 141

Alcon Acquires Endure Medical Systems, Technology Surgical Microscopes Provider 142

Novartis AG, Key Competitors 143

Novartis AG, Key Employees 144

Novartis AG, Subsidiaries 146

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Novartis AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 18103
Site License
USD 500 INR 36205
Corporate User License
USD 750 INR 54308

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com